Cited by 100Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related DiseasesIgG4-Related and Inflammatory Diseases

Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis

Open access
Lee, Joyce S., Kim, Eunice J., Lynch, Kara L., Elicker, Brett, Ryerson, Christopher J., Katsumoto, Tamiko R., Shum, Anthony K., Wolters, Paul J. +5 more·2013·Respiratory Medicine

Abstract

Background The clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis is unclear. The objective of this study was to determine the frequency and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.Methods We measured an extensive panel of autoantibodies (including rheumatoid factor, anti-cyclic citrullinated peptide, and anti-nuclear antibodies by immunofluorescence) associated with connective tissue disease or vasculitis in a cohort of well-characterized patients with idiopathic pulmonary fibrosis (n = 67). The prevalence of circulating autoantibodies was compared between idiopathic pulmonary fibrosis patients and healthy controls (n = 52). We compared the clinical characteristics of patients with and without circulating autoantibodies, and analyzed the relationship between autoantibody positivity and transplant-free survival time.Results Positive autoantibodies were found in 22% of patients with IPF and 21% of healthy controls. There were no differences in the types of autoantibodies found between patients with idiopathic pulmonary fibrosis and healthy controls. Among patients with idiopathic pulmonary fibrosis, there were no significant differences in clinical characteristics between those with and without circulating autoantibodies. The presence of circulating autoantibodies was associated with longer transplant-free survival time on adjusted analysis, however the significance varied depending on which statistical model was used (HR 0.22-0.47, p value 0.02-0.17).Conclusions The frequency of circulating autoantibodies in patients with idiopathic pulmonary fibrosis is no different compared to healthy controls, but may be associated with longer survival.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.rmed.2012.10.018

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A variety of novel autoantibodies targeting neoepitopes have been reported in IPF, with many targets being structural cell proteins such as desmoplakin and periplakin.

    “A variety of novel autoantibodies targeting neoepitopes have been reported in IPF (159–163), with many of the targets being structural cell proteins, such as desmoplakin (164) and periplakin (159).”
  • Patients with low-level titers of autoantibodies might have worsened clinical outcomes than those lacking these findings.

    “patients with low level titers of autoantibodies might have worsened clinical outcomes than those patients lacking these findings (160).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 27 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Lee, J. S., Kim, E. J., Lynch, K. L., Elicker, B., Ryerson, C. J., Katsumoto, T. R., Shum, A. K., Wolters, P. J., Cerri, S., Richeldi, L., Jones, K. D., King, T. E., & Collard, H. R.
Affiliations
  • University of California, San Francisco (US)
  • University of British Columbia (CA)
  • University of Modena and Reggio Emilia (IT)
Corresponding author
Lee, Joyce S.
Venue
Respiratory Medicine
Publisher
Elsevier BV
Published
2013-02
Volume
107
Issue
2
Pages
249-255
ISSN
0954-6111 (ISSN-L)
OpenAlex
W2160384627
Cited by
100
References
27
Citations by year
2026: 2 · 2025: 4 · 2024: 4 · 2023: 10 · 2022: 4 · 2021: 9 · 2020: 6 · 2019: 12 · 2018: 14 · 2017: 7 · 2016: 6 · 2015: 8 · 2014: 9 · 2013: 5
FWCI
5.68
Type
journal article
Language
en
Open access
Locations
  • Respiratory Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
  • ePrints Soton (University of Southampton) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institutes of Health
  • University of California, San Francisco
  • National Heart, Lung, and Blood Institute (HL086516, F32HL097383, HL097383, K08HL095659, K23HL086516)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
  • Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
Keywords
idiopathic pulmonary fibrosis, serum autoantibodies, autoantibody prevalence, rheumatoid factor, anti-CCP antibodies, antinuclear antibodies, connective tissue diseases, vasculitis, transplant-free survival, prognosis
MeSH terms
Aged, Aged, 80 and over, Autoantibodies, Female, Humans, Male, Middle Aged, Phenotype, Prognosis, Case-Control Studies, Lung Transplantation, Kaplan-Meier Estimate, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review